Drug - Lynparza™ (olaprarib capsules) [AstraZeneca]
November 2015
Therapeutic area - Oncology
The patient must meet all of the following criteria:
Maximum of 544 capsules per 34 days
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
MHCP Provider Call Center 651-431-2700 or 800-366-5411